Darbepoetin Alfa (Aranesp) Global Market Report 2024

The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.56 billion in 2023 to $5.88 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed during the historical period can be attributed to several factors, including advancements in the treatment of anemia, increased demand for erythropoiesis-stimulating agents (ESAs), innovations in biopharmaceuticals, greater clinical acceptance of these treatments, and the consequent improvement in patient outcomes. These elements collectively contributed to the expansion and development of therapies aimed at addressing anemia-related conditions.

The darbepoetin alfa (aranesp) market size is expected to see steady growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to several key factors, including the impact of healthcare reimbursement policies, heightened awareness and educational initiatives, ongoing development of healthcare infrastructure, rising demands for renal care, and the increasing population of older adults. These elements are expected to significantly contribute to the expansion of treatments related to anemia. Major trends projected for this period encompass the global market expansion, integration of digital health technologies into healthcare practices, the adoption of personalized treatment approaches, the increased utilization of biosimilars, and the development of long-acting formulations. These trends are poised to shape the future landscape of anemia treatments and healthcare delivery, fostering advancements and improvements in patient care and management.

The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Darbepoetin alfa is used to treat various chronic diseases, to reverse chemotherapy-induced anemia in cancer. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

The rising prevalence of diabetes is expected to propel the growth of the darbepoetin alfa market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. Over time, this condition causes major harm to the heart, blood vessels, eyes, kidneys, nerves, and other organs. Darbepoetin alfa plays a crucial role in diabetes patients by addressing the anemia associated with the condition, promoting red blood cell production, and improving overall quality of life. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed. According to IDF predictions, 783 million adults, or one in eight people, will have diabetes by 2045. This would represent a 46% rise, more than double the projected population growth for the same period (20%). Therefore, the rising prevalence of diabetes is driving the growth of the darbepoetin alfa market.

Product innovation stands out as a significant trend gaining momentum in the darbepoetin alfa market, with major companies strategically adopting new technologies to secure their market positions. GlaxoSmithKline Ltd., a UK-based pharmaceutical and biotechnology company, exemplifies this trend by introducing Jesduvroq (daprodustat) in February 2023. The US Food and Drug Administration (FDA), a US-based government agency, approved Jesduvroq as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the once-daily treatment of anemia induced by chronic kidney disease (CKD) in individuals on dialysis for at least four months.

Major companies in the darbepoetin alfa market are intensifying their focus on introducing novel medications to gain a competitive advantage. A case in point is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to address anemia associated with chronic kidney disease. Akebia Therapeutics, a US-based biotechnology company, obtained approval from Australia's Therapeutic Goods Administration (TGA) for Vafseo in September 2023. This approval extends to 36 countries, including Taiwan, and is based on the positive outcomes from the global Phase 3 clinical program demonstrating the efficacy of vadadustat in treating anemia due to CKD in adults on chronic maintenance dialysis. The commitment to introducing innovative products reflects the dedication of major companies in advancing solutions within the darbepoetin alfa market.

In July 2021, Chong Kun Dang Pharmaceutical, a leading pharmaceutical company based in South Korea, forged a partnership with Menagen Pharmaceutical Industries to distribute a darbepoetin alfa biosimilar across the Middle Eastern market, particularly targeting the Gulf Cooperation Council (GCC) nations. This collaboration encompasses technology transfer, manufacturing, and the commercialization of the darbepoetin alfa biosimilar. Menagen Pharmaceutical Industries, headquartered in Oman, specializes in the development and manufacturing of various specialized therapeutic products.

Major companies operating in the darbepoetin alfa (aranesp) market report are Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Iko Pharmaceutical Co. Ltd., Menagen Pharmaceutical Industries, Kyowa Kirin Co. Ltd., Polifarma S.p.A.

North America was the largest region in the darbepoetin alfa market in 2023. The regions covered in the darbepoetin alfa (aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the darbepoetin alfa (aranesp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary variations of darbepoetin alfa (Aranesp) include Epogen, Procrit, Aranesp, and other related forms. Epogen is a synthetic protein designed to boost the body's red blood cell production and is specifically employed to address anemia, characterized by a deficiency of red blood cells. These medications are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and find application in treating patients with chronic kidney disease, individuals with cancer, and other relevant medical conditions.

The darbepoetin alfa market research report is one of a series of new reports that provides darbepoetin alfa market statistics, including darbepoetin alfa industry global market size, regional shares, competitors with darbepoetin alfa market share, detailed darbepoetin alfa market segments, market trends, and opportunities, and any further data you may need to thrive in the darbepoetin alfa industry. This darbepoetin alfa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The darbepoetin alfa market consists of sales of Aranesp sure click, Aranesp albumin free, and Aranesp sing eject. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.